EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-SA 4.0

The Role of Genetic Testing in Uro-oncology: A Comprehensive Summary

Pranjal Chowdhury, Prasant Nayak, Swarnendu Mandal, Manoj Kumar Das, Sambit Tripathy

Journal of Association of Southern Urologists · 2025

DOI: 10.4103/jasu.jasu_13_25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Association of Southern Urologists, 2025. Verfasst von Pranjal Chowdhury und 4 weiteren Autor:innen. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-SA 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The integration of genetic testing into uro-oncology has significantly changed the management of genito-urinary malignancy by ushering forward precision medicine. Our review highlights the current latest evidence on the clinical significance of germline and somatic testing across the spectrum of some genito-urinary malignancies which includes prostate, bladder cancer, renal cancer and UTUC. In prostate the BRCA 1 and 2 gene and other HRR gene mutations help guide use of PARP inhibitors. In bladder cancer, molecular subtyping and detection of FGFR alterations facilitate targeted therapies with checkpoint inhibitors now considered a standard in BCG unresponsive cases and metastatic cases. Similarly, Upper tract urothelial carcinoma (UTUC), has a strong association with Lynch syndrome, and patients particularly benefit from germline mismatch repair (MMR) testing. PROfound, CheckMate 274, and POUT were clinical trials that validated the prognostic and therapeutic implications of genetic abnormalities. The von Hippel-Lindau (VHL) protein regulates the hypoxia-inducible factor (HIF). Accumulation of HIF-2a causes a several-fold increase in the expression of vascular endothelial growth factor (VEGF). This led to development of various targetting agents VEGF-TKI inhibitors like sunitinib, pazopanib, cabozantinib. Also the combination of these TKIs with ICIs have led to a paradigm shift in treatment of metastatic RCC and are now considered first line as established in Checkmate 214, KEYNOTE-426, JAVELIN RENAL 101.

Zitieren

APA

Chowdhury, P., Nayak, P., Mandal, S., Das, M. K., & Tripathy, S. (2025). The Role of Genetic Testing in Uro-oncology: A Comprehensive Summary. Journal of Association of Southern Urologists. https://doi.org/10.4103/jasu.jasu_13_25

Vancouver

Chowdhury P, Nayak P, Mandal S, Das MK, Tripathy S. The Role of Genetic Testing in Uro-oncology: A Comprehensive Summary. Journal of Association of Southern Urologists. 2025. doi:10.4103/jasu.jasu_13_25

BibTeX
@article{Chowdhury2025,
  author = {Chowdhury, Pranjal and Nayak, Prasant and Mandal, Swarnendu and Das, Manoj Kumar and Tripathy, Sambit},
  title = {The Role of Genetic Testing in Uro-oncology: A Comprehensive Summary},
  journal = {Journal of Association of Southern Urologists},
  year = {2025},
  doi = {10.4103/jasu.jasu_13_25}
}
Kostenlos starten →